Moazzam Shahzad, MD
Moazzam Shahzad, MD
Specialty: Hematology/Oncology
Program: MMG Ambulatory HemOnc
Language(s): English
-
Overview
Cancer Focus:
Esophageal Cancer, Gastrointestinal Carcinoid Tumor, Kidney (Renal Cell) Cancer, Liver (Hepatocellular) Cancer, Lung Cancer, Prostate Cancer, Testicular CancerDr. Shahzad received his MBBS degree from Allama Iqbal Medical College, University of Health Sciences, Lahore, Pakistan. He completed an Internal Medicine Residency at One Brooklyn Health/Interfaith Medical Center, Brooklyn, New York, followed by a Hematology-Oncology Fellowship at the University of South Florida, Morsani College of Medicine, and Moffitt Cancer Center.
Dr. Shahzad’s clinical interests focus on delivering high-quality cancer care, with a particular emphasis on solid tumors and integrating evidence-based practices to improve patient outcomes, along with expanding access to novel therapies through clinical trial participation in underserved populations. His research interests focus on clinical trial development and real-world outcomes to improve care delivery, with emphasis on addressing disparities and advancing global oncology through collaborative efforts.
-
Publications
- Ullah A, Haider F, Ahmed F, Arham M, Dad A, Tareen H, Saleem F, Bakht K, Malik AN, Afzaal Z, Athar FB, Aman K, Zahid H, Asjid M, Ejaz S, Qureshi Z, Shahzad M. Comparative safety and efficacy of tislelizumab-based regimens versus chemotherapy in lung cancer: a systematic review and meta-analysis. Front Oncol. 2025 Oct.15:1628742. Pubmedid: 41127016. Pmcid: PMC12537389.
- Ahmed S, Ashraf H, Ashfaq H, Ahmad E, Akram U, Ali A, Ahmad S, Ahmed R, Amin MK, Shahzad M. Trends and disparities in immune thrombocytopenic purpura-related mortality in the United States: a retrospective study over 24 years. Hematology. 2025 Dec.30(1):2559334. Pubmedid: 40955623.
- Rehman AU, Ayoobkhan FS, Shahzad M, Amin MK, Shatnawi S, Irfan S, Chaudhary SG, Anwer F, McGuirk JP, Mohty M, Ahmed N, Abdallah AO, Mushtaq MU. Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines. Bone Marrow Transplant. 2025 Aug.60(8):1169-1174. Pubmedid: 40325139.
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments